Compare Agora Inc (API) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agora Inc vs TG Therapeutics Inc — how do they compare? Agora Inc trades at $4.18 (market cap $355.95M), while TG Therapeutics Inc trades at $55.24 (market cap $8.74B). The key difference: TG Therapeutics Inc is far larger — about 24.6× Agora Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Agora Inc nearer its low. Which is the better fit depends on your goals.
| API | TGTX | |
|---|---|---|
Market Cap | $355.95M | $8.74B |
Sector | Technology | Health |
52-Week High | $5.26 | $59.06 |
52-Week Low | $3.24 | $26.39 |
Enterprise Value | $108.94M | $8.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agora, Inc. (API) trades at $4.22, down 2.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue above guidance and its sixth consecutive quarter of GAAP profitability, with net income of $9.53 million in 2025. Recent news highlights management share purchases and a partnership with thymia for real-time health intelligence.
Outlook remains positive with analyst consensus at 60% buy ratings, supported by strong cash flow growth and a low P/B of 0.64. Key risks include competitive pressures in conversational AI and potential volatility from high short interest growth of 30.3% as of March 31, 2026 (Defense World).
TG Therapeutics (TGTX) trades at $57.12, down 3.28% on the day, amid mixed technical signals. The stock exhibits strong profitability with a net income margin of 65.95% and robust revenue growth, reaching $616.29 million in 2025. Recent positive news includes the initiation of a Phase II trial for Briumvi in schizophrenia and strong sales momentum, though recent quarterly EPS results have missed expectations. The technical outlook is bullish based on moving averages, but oscillators show bearish pressure with RSI levels indicating potential overbought conditions.
The investment outlook for TGTX is supported by strong analyst sentiment with 84.62% buy ratings and a consensus price target of $45.00, though the current price exceeds this target. Key opportunities include pipeline expansion and rising Briumvi demand, but risks involve clinical trial outcomes, competitive pressures, and cash flow volatility. Investors should weigh the high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
